Work

2613MO Identifying biomarkers of response to first-line nivolumab plus ipilimumab therapy in patients with metastatic clear cell renal cell carcinoma (mccRCC) enrolled in the COSMIC 313 trial

Year: 2025

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2025.08.3228

Authors: B. Simsek, S.M. Niman, N. El Ahmar, R.A. Mohanna, A. Delcea, G.R. De Oliveira, Y.N. Laimon, L. Ascione, W. Xie, D.A. Braun, M. Sun, E. Saad, J. El Masri, G.J. Freeman, A. Simmons, D. Aftab, R.J. Motzer, M.B. Atkins, T.K. Choueiri, S. Signoretti

Institutions: Brigham and Women's Hospital, Dana-Farber Cancer Institute, Yale Cancer Center, Yale University, Exelixis (United States), Memorial Sloan Kettering Cancer Center, Georgetown University, Georgetown Lombardi Comprehensive Cancer Center, Harvard University, Dana-Farber Brigham Cancer Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4415940606

FWCI: 0.72

Cites:

Cited by: 2

Related to: